Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 19 November 2021

Date: 19/11/2021
Location: Online

This extraordinary plenary meeting is organised in the context of the Article 5(3) reviews of COVID-19 treatments Lagevrio (molnupiravir) and Paxlovid (PF-07321332 / ritonavir).

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.

How useful was this page?

Add your rating
1 rating